RNA vs. NAMS, RCKT, GLPG, AMRX, EVO, GPCR, AMPH, AGIO, KROS, and SNDX
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include NewAmsterdam Pharma (NAMS), Rocket Pharmaceuticals (RCKT), Galapagos (GLPG), Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), Keros Therapeutics (KROS), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
Avidity Biosciences (NASDAQ:RNA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.
In the previous week, Avidity Biosciences had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Avidity Biosciences and 5 mentions for NewAmsterdam Pharma. Avidity Biosciences' average media sentiment score of 0.56 beat NewAmsterdam Pharma's score of 0.01 indicating that Avidity Biosciences is being referred to more favorably in the media.
NewAmsterdam Pharma has higher revenue and earnings than Avidity Biosciences.
Avidity Biosciences has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
NewAmsterdam Pharma has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,219.87%. NewAmsterdam Pharma's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Avidity Biosciences currently has a consensus target price of $36.86, indicating a potential upside of 39.35%. NewAmsterdam Pharma has a consensus target price of $33.25, indicating a potential upside of 52.38%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Avidity Biosciences.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.0% of Avidity Biosciences shares are held by company insiders. Comparatively, 2.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Avidity Biosciences received 124 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.29% of users gave Avidity Biosciences an outperform vote.
Summary
NewAmsterdam Pharma beats Avidity Biosciences on 9 of the 15 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
